Analytical Data
-
Gene name
SMN2
- Application
-
Alternative Names
SMN2；SMN；SMNT；SMN2；Survival motor neuron Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q16637
-
Expression Region
2-294aa
-
AA Sequence
AMSSGGSGG GVPEQEDSVL FRRGTGQSDD SDIWDDTALI KAYDKAVASF KHALKNGDIC ETSGKPKTTP KRKPAKKNKS QKKNTAASLQ QWKVGDKCSA IWSEDGCIYP ATIASIDFKR ETCVVVYTGY GNREEQNLSD LLSPICEVAN NIEQNAQENE NESQVSTDES ENSRSPGNKS DNIKPKSAPW NSFLPPPPPM PGPRLGPGKP GLKFNGPPPP PPPPPPHLLS CWLPPFPSGP PIIPPPPPIC PDSLDDADAL GSMLISWYMS GYHTGYYMGF RQNQKEGRCS HSLN
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The SMN2 gene, a vertebrate homologue of the survival motor neuron (SMN) gene essential for motor neuron development, plays a critical role in the pathogenesis of spinal muscular atrophy (SMA), a severe genetic disorder characterized by the degeneration of motor neurons leading to muscle atrophy and weakness. The SMN2 gene produces a partial functional protein that is insufficient to prevent SMA due to alternative splicing, leading to the retention of intron 7, which results in the production of a truncated protein. Researchers have been focusing on the development of SMN2 recombinant proteins to better understand SMN function and to explore potential therapeutic strategies. These recombinant proteins are valuable tools for elucidating the molecular mechanisms underlying SMA and may aid in the identification of small molecules or compounds that enhance SMN2 expression or function. Recent advancements in gene therapy and drug development have brought renewed interest in targeting SMN2, making the study of its recombinant protein crucial for developing effective treatments for SMA. Through these efforts, there is hope for improving the quality of life for affected individuals and finding a cure for this debilitating condition.
